Literature DB >> 6410746

Treatment of cerebral arteriovenous malformations: combined neurosurgical and neuroradiologic approach.

L D Cromwell, A B Harris.   

Abstract

Experience with 31 intraoperative embolizations performed on 23 patients is reported. The procedure involves the direct injection of embolic material into the main arterial feeders during craniotomy. The combined effort involves the exposure of the lesion at craniotomy, standard arteriotomy, and fluoroscopically monitored intravascular infusion of contrast material followed by the injection of bucrylate (IBCA, Ethicon, Somerville, NJ) mixed with tantalum or Pantopaque into the feeding vessels and into the interstices of the malformation. It was concluded that the procedure significantly diminishes operating time and blood loss for the lesions that were subsequently resected. Fluoroscopy coupled with high-quality stop-frame videotape recording allows a detailed study of the flow characteristics of the malformation so that polymerization time can be regulated appropriately. Follow-up varied from 3 months to 4 1/2 years. There were two deaths related to the procedure and one additional complication of cortical blindness that partially resolved. None of the survivors rebled. Most of the survivors improved.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6410746      PMCID: PMC8334947     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  3 in total

1.  Early surgical treatment of intracerebral hemorrhages caused by AVM: our experience in 10 cases.

Authors:  F Puzzilli; L Mastronardi; A Ruggeri; P Lunardi
Journal:  Neurosurg Rev       Date:  1998       Impact factor: 3.042

Review 2.  Interventional neuroradiology.

Authors:  S L Barnwell
Journal:  West J Med       Date:  1993-02

3.  Surgical treatment of cerebral arteriovenous malformations. Follow-up study of 43 cases.

Authors:  D Adelt; H Zeumer; J Wolters
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.